3D MEDICINES INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.42 HKD | +0.16% |
|
-13.59% | -15.97% |
| Mar. 29 | 3D Medicines' 2023 Loss Almost Halves as Revenue Jumps 12% | MT |
| Mar. 28 | 3D Medicines Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2022 | 2023 |
|---|---|---|
| Capitalization 1 | 8,383 | 1,575 |
| Enterprise Value (EV) 1 | 7,616 | 860.5 |
| P/E ratio | -1.67 x | -3.02 x |
| Yield | - | - |
| Capitalization / Revenue | 14,773,952 x | 2,479,941 x |
| EV / Revenue | 13,423,339 x | 1,355,202 x |
| EV / EBITDA | -17.6 x | -1.76 x |
| EV / FCF | -49,450,242 x | 7,186,264 x |
| FCF Yield | -0% | 0% |
| Price to Book | 8.92 x | 1.82 x |
| Nbr of stocks (in thousands) | 223,327 | 226,760 |
| Reference price 2 | 37.54 | 6.944 |
| Announcement Date | 4/28/23 | 4/28/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Net sales | - | 60.26 | 567.4 | 634.9 |
| EBITDA 1 | -303.3 | -516.8 | -431.7 | -489.4 |
| EBIT 1 | -304.5 | -520.5 | -439.6 | -497.2 |
| Operating Margin | - | -863.81% | -77.47% | -78.31% |
| Earnings before Tax (EBT) 1 | -635.4 | -1,462 | -1,052 | -562.5 |
| Net income 1 | -635.4 | -1,434 | -1,024 | -524.7 |
| Net margin | - | -2,379.84% | -180.54% | -82.64% |
| EPS 2 | -13.93 | -36.72 | -22.52 | -2.297 |
| Free Cash Flow | - | -192.3 | -154 | 119.7 |
| FCF margin | - | -319.13% | -27.15% | 18.86% |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 11/28/22 | 11/28/22 | 4/28/23 | 4/28/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Net Debt 1 | 1,252 | 2,367 | - | - |
| Net Cash position 1 | - | - | 766 | 714 |
| Leverage (Debt/EBITDA) | -4.126 x | -4.58 x | - | - |
| Free Cash Flow | - | -192 | -154 | 120 |
| ROE (net income / shareholders' equity) | - | 82.5% | 153% | -63.7% |
| ROA (Net income/ Total Assets) | - | -41.8% | -23% | -22.5% |
| Assets 1 | - | 3,431 | 4,460 | 2,331 |
| Book Value Per Share 2 | -27.80 | -61.40 | 4.210 | 3.820 |
| Cash Flow per Share 2 | 9.080 | 21.20 | 3.110 | 2.720 |
| Capex 1 | 11.1 | 43.9 | 54 | 6.32 |
| Capex / Sales | - | 72.8% | 9.51% | 1% |
| Announcement Date | 11/28/22 | 11/28/22 | 4/28/23 | 4/28/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -15.97% | 201M | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.67% | 12.27B |
- Stock Market
- Equities
- 1244 Stock
- Financials 3D Medicines Inc.
